Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Merck

Revenues up 8% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck
1Q Revenues: $10.8 billion (+ 8%)
1Q Earnings: $2.9 billion (earnings were $736 million 1Q18)
Comments: Keytruda sales were $2.3 billion in the quarter, up 55%. JANUVIA sales were down 5% to $1.4 billion due to continuing pricing pressure in the U.S. Growth in the quarter was partially offset by the ongoing impacts from the loss of market exclusivity for ZETIA and VYTORIN with sales down 50% to $238 million. Growth in vaccines was driven largely by GARDASIL, with sales of $838 million, up 27%. VARIVAX sales were up 27% to $496 million. BRIDION, for the reversal of neuromuscular blockade, had sales of $255 million, up 25%. International sales represented 58% of total sales in the quarter led by China, which had sales growth of 58%, driven by vaccines and oncology.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters